97933982 - PEPTIDREAM

Information

• Trademark
• 97933982

• Source

• Serial Number

  97933982

• Registration Number

  7709589

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 5 - Pharmaceutical and veterinary preparations
  • 35 - Advertising
  • 40 - Treatment of materials
  • 42 - Scientific and technological services and research and design relating thereto

• Filing Date

  May 12, 2023
  2 years ago

• Registration Date

  March 04, 2025
  3 months ago

• Transaction Date

  March 04, 2025
  3 months ago

• Status Date

  March 04, 2025
  3 months ago

• Published for Opposition Date

  January 14, 2025
  4 months ago

• Location Date

  March 03, 2025
  3 months ago

• Status Code

  700

• Current Location

  FILE REPOSITORY (FRANCONIA)

  Employee Name

  DAWE III, BILL

• Attorney Docket Number

  PPDM 13732

  Attorney Name

  Harris A. Wolin

• Owners

  • Peptidream Inc.

Case File Statements

• GS0401: Manufacture of synthetic peptides to the order and specification of others; Peptide synthesis for others, namely, manufacture of synthetic peptides to the order and specification of others; Manufacture of pharmaceuticals and chemicals to the order and specification of others; Manufacture of synthetic proteins to the order and specification of others; Amino acid synthesis for others, namely, manufacture of amino acids to the order and specification of others
• GS0051: Synthesized peptides used in drug discovery of various pharmaceuticals for the treatment of various to different diseases and medical conditions; Chemical preparations used in drug discovery for the treatment of various diseases and medical conditions and for pharmaceutical purposes; Central nervous system drugs, namely, pharmaceutical preparations for the treatment of various diseases and medical conditions affecting the central nervous system; Peripheral nerve drugs, namely, pharmaceutical agents for the treatment of various diseases and medical conditions affecting the peripheral nervous system; Drugs affecting sensory organs, namely, pharmaceutical agents for the treatment of various diseases and medical conditions affecting sensory organs; Antiallergic drugs, namely, pharmaceutical antiallergic preparations and substances; Cardiovascular drugs, namely, cardiovascular pharmaceutical preparations; Drugs affecting respiratory organs, namely, pharmaceutical preparations for treating respiratory diseases; Drugs affecting digestive organs, namely, pharmaceutical preparations for the treatment of various diseases and medical conditions affecting digestive organs; Drugs for outer skin, namely, pharmaceutical preparations for the treatment of various diseases and medical conditions for skin care; Pharmaceutical preparations for the treatment of various diseases and medical conditions of Metabolic disorders; Cellular function activating drugs for the treatment of various diseases and medical conditions for medical purposes; Pharmaceutical preparations for the treatment of various diseases and medical conditions for suppressing tumors; diagnostic preparations for medical purposes; Pharmaceutical preparations using synthesized peptides used in drug discovery and pharmaceuticals for the treatment of various diseases and medical conditions for medical purposes; Synthesized proteins and chemical preparations used in drug discovery and pharmaceuticals for the treatment of various diseases and medical conditions for medical purposes
• GS0351: Retail and wholesale store services featuring chemicals; Retail and wholesale store services featuring pharmaceuticals and medical supplements
• GS0011: Chemicals for the manufacture of pharmaceuticals; synthesized peptides for scientific and research use; Reagents for biological and chemical purposes and for research purposes, excluding those for medical or veterinary use; Proteins and synthesized peptides used in the research and the development and manufacture of pharmaceuticals and biologicals; Chemical reagents used for the detection, measurement and identification of genetic materials or compounds, excluding those for medical and veterinary use
• GS0421: Testing, examination, namely, inspection and research services in the field of pharmaceuticals, cosmetics, and foods, and the provision of information or advice thereto; Testing, examination, namely, inspection and research services in the field of medical organisms or bacteria, and the provision of information or advice thereto; Testing, examination, namely, inspection and research services in the field of chemistry, and the provision of information or advice thereto; Testing, examination, namely, inspection and research services in the field of medical care, and the provision of information or advice thereto; Testing, examination, namely, inspection and research services in the field of biotechnology, and the provision of information or advice thereto; Testing, examination, namely, inspection and research services in the field of the identification of hit lead peptides, and the provision of information or advice thereto; Testing, examination, namely, inspection and research services in the field of the identification of hit-lead compounds, and the provision of information or advice thereto; Testing, examination, namely, inspection and research services in the field of the analysis and synthesis of peptides, and the provision of information or advice thereto; Testing, examination, namely, inspection and research services in the field of the analysis and synthesis of proteins, and the provision of information or advice thereto; The generation of a library of peptides and the provision of information or advice thereto; Testing, examination, namely, inspection and research services in the fields of pharmaceuticals, cosmetics, foods, medical organisms or bacteria, chemistry, medical care, biotechnology, identification of hit lead peptides, analysis and synthesis of peptides, using automated screening machines and the provision of information or advice thereto; Scientific research in the nature of conduction of clinical trials for others; Quality control of peptides used in drug development; Advice on quality control of peptides used in drug development

Case File Event Statements

• 5/16/2023 - 2 years ago

  1 - NEW APPLICATION ENTERED Type: NWAP

• 6/12/2023 - a year ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 2/6/2024 - a year ago

  3 - ASSIGNED TO EXAMINER Type: DOCK

• 2/7/2024 - a year ago

  4 - NON-FINAL ACTION WRITTEN Type: CNRT

• 2/7/2024 - a year ago

  5 - NON-FINAL ACTION E-MAILED Type: GNRT

• 2/7/2024 - a year ago

  6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 2/8/2024 - a year ago

  7 - NON-FINAL ACTION WRITTEN Type: CNRT

• 2/8/2024 - a year ago

  8 - NON-FINAL ACTION E-MAILED Type: GNRT

• 2/8/2024 - a year ago

  9 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 5/7/2024 - a year ago

  10 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 9/18/2024 - 8 months ago

  12 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 9/24/2024 - 8 months ago

  15 - NON-FINAL ACTION E-MAILED Type: GNRT

• 9/24/2024 - 8 months ago

  14 - NON-FINAL ACTION WRITTEN Type: CNRT

• 9/24/2024 - 8 months ago

  16 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 12/10/2024 - 5 months ago

  18 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 12/10/2024 - 5 months ago

  19 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 12/10/2024 - 5 months ago

  17 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 12/13/2024 - 5 months ago

  20 - ASSIGNED TO LIE Type: ALIE

• 12/13/2024 - 5 months ago

  21 - DATA MODIFICATION COMPLETED Type: DMCC

• 12/17/2024 - 5 months ago

  24 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN

• 12/17/2024 - 5 months ago

  22 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA

• 12/17/2024 - 5 months ago

  23 - EXAMINERS AMENDMENT E-MAILED Type: GNEA

• 12/17/2024 - 5 months ago

  25 - EXAMINER'S AMENDMENT ENTERED Type: XAEC

• 12/18/2024 - 5 months ago

  26 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 1/8/2025 - 5 months ago

  27 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 1/14/2025 - 4 months ago

  28 - PUBLISHED FOR OPPOSITION Type: PUBO

• 1/14/2025 - 4 months ago

  29 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 3/4/2025 - 3 months ago

  30 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC

• 3/4/2025 - 3 months ago

  31 - REGISTERED-PRINCIPAL REGISTER Type: R.PR

• 9/19/2024 - 8 months ago

  11 - ASSIGNED TO LIE Type: ALIE

• 9/18/2024 - 8 months ago

  13 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME